Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC.docx

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC.docx

Background<p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-based combination therapy modalities for patients with EGFR-mutated stage IV non-small cell lung cancer (NSCLC) are being investigated. We evaluated the value and safety of third-generation EGFR-TKIs combined...

Повний опис

Збережено в:

Бібліографічні деталі
Автор:	Xinhang Gu (22686224) (author)
Інші автори:	Jiaxiao Geng (22509188) (author), Hongfu Sun (10054227) (author), Qiang Cao (119096) (author), Yan Yi (504321) (author), Baosheng Li (290758) (author)
Опубліковано:	2025
Предмети:	Oncology and Carcinogenesis not elsewhere classified non-small cell lung cancer radiotherapy epidermal growth factor receptor tyrosine kinase inhibitor radiation dosage
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Table 1_Selected parameters of epidermal barrier in juveniles with type 1 diabetes correspond with the severity of diabetes – an observational study.docx
за авторством: Klaudia Bogusz-Górna (22678724)
Опубліковано: (2025)

Data Sheet 1_Intra-voxel incoherent motion biomarker repeatability in healthy volunteers and sensitivity to chemoradiotherapy-induced changes in patients with uterine cervical cancer.pdf
за авторством: Damien J. McHugh (22686269)
Опубліковано: (2025)

Dimensionality-Tailored Pure Organic Semiconductor with High Hole Mobility for Low-dose X-ray Imaging
за авторством: Yadong Xu (22081557)
Опубліковано: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
за авторством: Seung Yeon Oh (15051017)
Опубліковано: (2025)

Supplementary Table S10 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
за авторством: Anfal Alsadhan (15907475)
Опубліковано: (2025)

Supplementary Table S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
за авторством: Anfal Alsadhan (15907475)
Опубліковано: (2025)

Supplementary Table S5 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
за авторством: Anfal Alsadhan (15907475)
Опубліковано: (2025)

Supplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
за авторством: Anfal Alsadhan (15907475)
Опубліковано: (2025)

Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
за авторством: Anfal Alsadhan (15907475)
Опубліковано: (2025)

Supplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
за авторством: Anfal Alsadhan (15907475)
Опубліковано: (2025)

Supplementary Table S9 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
за авторством: Anfal Alsadhan (15907475)
Опубліковано: (2025)

Figure S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
за авторством: Upendra Kumar Soni (15051683)
Опубліковано: (2025)

Figure S2 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
за авторством: Upendra Kumar Soni (15051683)
Опубліковано: (2025)

Figure S3 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
за авторством: Upendra Kumar Soni (15051683)
Опубліковано: (2025)

Figure S4 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
за авторством: Upendra Kumar Soni (15051683)
Опубліковано: (2025)

Figure S5 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
за авторством: Upendra Kumar Soni (15051683)
Опубліковано: (2025)

Figure S6 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
за авторством: Upendra Kumar Soni (15051683)
Опубліковано: (2025)

Supplementary Data File S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
за авторством: Upendra Kumar Soni (15051683)
Опубліковано: (2025)

eGFR in the study participants.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Stratification of Liver Stiffness according to eGFR in the MAFLD group.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

NagS is a conserved protein amongst Streptomycete organisms.
за авторством: Chao Li (145513)
Опубліковано: (2025)

<i>Toxoplasma gondii</i> tachyzoite cell organization.
за авторством: Romuald Haase (22339777)
Опубліковано: (2025)

Table 1_Clinical study on the effects of different cold compress methods and durations on postoperative complications following mandibular impacted third molar extraction.docx
за авторством: Zhiwen Xie (6335777)
Опубліковано: (2025)

Integrated workflow for organism-level phenotyping and machine-learning inference.
за авторством: Zhuangbin Zheng (22676304)
Опубліковано: (2025)

A. Violin plots showing eGFR distribution in MAFLD (red) vs. non-MAFLD (blue) groups.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_nrnuhiftvpk4310ngv8rs299f0